Yuto Matsushita
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Objectives This study aimed to assess the prognostic outcomes and risk of adverse events in elderly non-muscle invasive bladder cancer (NMIBC) patients receiving photodynamic diagnosis-assisted transurethral resection of bladder cancer (PDD-TURBT). Methods This study retrospectively included 326 patients who were over 70 years old and received either PDD-TURBT (n = 114, PDD group) or white-light TURBT (n = 212, WL group). Oncological outcomes, namely recurrence-free survival (RFS) and progression-free survival (PFS), and adverse event profiles were compared between the two groups. Results In the PDD and WL groups, the median RFS periods were not reached and 41.7 months (P < 0.001), and the median PFS periods were not reached and 160.2 months (P = 0.057), respectively. The Grey test which take account to overall death as a competing risk event revealed recurrence tended to decrease in PDD group (P = 0.050). The independent prognostic factors were determined by multivariate Cox regression analyses: WL-TURBT in RFS. After propensity score matching, statistically favorable RFS in the PDD group were shown (P = 0.018). The incidence of AST/ALT elevation and intraoperative hypotension (defined as systolic blood pressure ≤ 80 mmHg) were significantly higher in the PDD group than in the WL group (P = 0.003 and 0.003, respectively). Conclusions Prolonged RFS are expected for PDD-TURBT using oral 5-aminolevulinic acid in elderly NMIBC patients. However, the risks of liver injury and intraoperative hypotension are higher for PDD-TURBT.
Year:
2025
Introduction This study aimed to assess the perioperative outcomes during the learning period for robot‐assisted radical prostatectomy (RARP) using multiple surgical robot systems, namely hinotori and da Vinci, and compare them with those observed for surgeons trained using only da Vinci. Methods This study included two surgeons who learned RARP using multiple robot systems (hinotori and da Vinci Xi [H&D] group) and four surgeons who learned using only da Vinci (D group). We retrospectively collected data from the initial 25 cases of each surgeon. Perioperative outcomes, including the time using the robotic system, PSA recurrence, and urinary continence at 3 months after surgery, were compared between the two groups. Results The patient characteristics were not significantly different between the two groups. The H&D group surgeons had shorter experience as urologists and laparoscopic surgeons but had extensive experience as assistants of RARP, and the institutional experience with RARP was greater in the H&D group. The perioperative outcomes, specifically the time using the robotic system, PSA recurrence rate, and pad‐free rate at 3 months after surgery, did not significantly differ between the two groups. The multivariate analysis indicated that the time using the robotic system and pad‐free rate were not significantly different between the two groups. Conclusions The perioperative outcomes during the RARP learning period using both hinotori and da Vinci were not significantly different from those using only da Vinci; although the H&D group surgeons in training were relatively younger, they had slightly more practice as RARP assistants at a more experienced institution.
Year:
2025
Objectives To evaluate the impact of age on treatment patterns and outcomes in patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). Methods We conducted a retrospective multicenter analysis of 428 patients with nmCRPC from 25 tertiary centers (2002–2022). Patients were divided into two age groups: < 80 and ≥ 80 years. The outcomes included cancer‐specific survival (CSS), overall survival (OS), and progression‐free survival (PFS). Results Among 428 patients (median follow‐up, 32.5 months), performance status (PS) 0 was more frequent in < 80 vs. ≥ 80 years (78% vs. 58%, p < 0.001). Use of first‐line androgen receptor signaling inhibitors (ARSIs) was similar (58% vs. 59%, p = 0.83) among all, whereas any‐line docetaxel use was less common in patients aged ≥ 80 years (33% vs. 9% for < 80 vs. ≥ 80, p < 0.001). Five‐year CSS was 76.5% vs. 63.7% ( p = 0.002) and five‐year OS 73.8% vs. 59.9% ( p = 0.006) for < 80 vs. ≥ 80 years, respectively. Time‐to‐treatment failure was shorter in patients aged ≥ 80 years ( p = 0.04). Conclusion Maintaining PS and managing ARSI‐related adverse events are essential in older patients with nmCRPC and may preserve their eligibility for chemotherapy and improve their prognosis.
Year:
2025
Introduction Upper pole renal tumors, despite the unique surgical techniques and preparations necessitated by their anatomical location, are assigned the same numerical complexity as lower pole tumors by the RENAL nephrometry score. Consequently, this study aimed to compare the perioperative outcomes of robot‐assisted partial nephrectomy (RAPN) for upper versus lower pole renal tumors. Methods Out of 484 consecutive patients who underwent RAPN at our institution, this retrospective study included 186 patients with renal polar tumors. Upper and lower pole tumors were defined as those with a RENAL nephrometry score L component of 1, indicating polar tumors not overlapping the superior or inferior polar lines. RAPN procedures were performed using either the da Vinci Xi or the hinotori system, a newly developed robotic platform in Japan. For upper pole tumor excision in a transperitoneal approach, a 30° down‐angle robotic camera was inserted via a camera port previously positioned approximately 3 cm more superolaterally than the standard placement, alongside two robotic arms, irrespective of the robotic platform. Results The study population was divided into lower ( n = 109) and upper ( n = 77) pole tumor groups; tumors located centrally, including hilar tumors, were entirely excluded. No significant differences were observed in baseline patient characteristics between the two groups. Following surgery, significant differences were found in operative time (165 vs. 179 min, p = 0.010) and robotic time (98 vs. 116 min, p = 0.004) between the lower and upper pole groups, respectively. However, other major perioperative outcomes, including the Trifecta achievement rate (94.5% vs. 98.7%, p = 0.24), showed no significant differences. Uni‐ and multivariate analyses identified sex, tumor size, and tumor polar location as independent factors for prolonged robotic time; however, robotic platform type was not. Conclusions With proper technical preparation, RAPN for upper pole tumors can achieve comparable perioperative outcomes to that for lower pole tumors, despite requiring longer operative and robotic times.
Year:
2025
Introduction Partial splenic embolization is a valuable option to manage hypersplenism and reduce portal pressure while preserving splenic function. It may improve surgical safety in patients with portal hypertension. Case Presentation A 67‐year‐old Japanese male with renal cell carcinoma and hepatitis B‐related liver cirrhosis presented with thrombocytopenia, collateral vessels, and a splenorenal shunt. Due to concerns regarding surgical risk, partial splenic embolization was performed preoperatively. Following the procedure, the platelet count increased, and collateral circulation decreased. These improvements enabled a safe left radical nephrectomy. Conclusion Partial splenic embolization can be an effective preoperative strategy in patients with renal tumors and coexisting portal hypertension. By improving hematologic parameters and reducing vascular risk, it may facilitate curative surgery in high‐risk patients and expand treatment options.
Year:
2025
Radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) poses significant challenges due to the impact on renal function. A kidney‐sparing strategy (KSS) is considered for patients with low‐risk disease or compromised renal function to avoid the morbidity associated with RNU. Endoscopic management, including ureteroscopy with laser ablation, offers a minimally invasive approach for low‐grade, small tumors, preserving renal function while achieving cancer control. Segmental ureteral resection is suitable for only selected cases, balancing oncologic efficacy with nephron preservation. Intracavitary instillations of mitomycin or Bacille Calmette–Guerin (BCG) enhance local control in carefully selected patients. Advances in imaging and biomarkers improve patient selection and monitoring after KSS. These strategies require multidisciplinary coordination to optimize outcomes while preserving renal function. Long‐term surveillance is essential due to high recurrence rates. Kidney‐preserving approaches, when appropriately applied, improve quality of life and reduce surgery‐related morbidity while maintaining oncologic control in patients with UTUC. In this manuscript, we discuss the potency of improved outcomes based on our experience.
Year:
2025
Introduction Multiple synchronous renal tumors (MSRT) in unilateral kidney are clinically rare. Simultaneous resection for multiple tumors with RAPN is complicated and challenging. Herein, we report the successful resection of three synchronous renal tumors located in unilateral kidney with RAPN using the hinotori surgical robot system. Case Presentation A 75‐year‐old man was diagnosed with multiple left renal tumors (45 mm and 20 mm in diameter) that presented very close to each other. We performed RAPN using hinotori and excised the tumors simultaneously. Postoperative renal function was maintained. No complications were identified. The three histological types were distinct: ccRCC, pRCC, and small renal angiomyolipoma. Conclusion To the best of our knowledge, this is the first report of MSRT in unilateral kidney successfully treated with RAPN using hinotori.
Year:
2025
Introduction Robot‐assisted radical cystectomy (RARC) is becoming the standard treatment for bladder cancer patients. While this surgery using da Vinci has been widely reported, this report describes the initial experience of RARC with intracorporeal neobladder using the hinotori surgical robot system. Case Presentation The patient was a 73‐year‐old man with muscle‐invasive bladder cancer who underwent neoadjuvant chemotherapy followed by RARC with intracorporeal neobladder using hinotori. Surgery was successfully performed with a total operative time of 430 min, time using the robotic system of 375 min, and no intraoperative complications or need for blood transfusion. Postoperative recovery was favorable, with the patient discharged on day 12, and satisfactory continence was achieved. Conclusions This is the initial case report of RARC with intracorporeal neobladder using hinotori, providing a potentially comparable alternative to conventional surgical systems for RARC.
Year:
2025
Objectives The aim of this study was to compare clinical outcomes between patients receiving second TUR after initial white‐light transurethral resection of bladder tumor (WL‐TURBT) and initial photodynamic diagnosis (PDD)‐assisted TURBT. Methods A total of 1007 patients were divided into four groups based on the treatment pattern: WL‐TURBT with second TUR (161 patients, WL‐second group) or without second TUR (540 patients, WL‐alone group) and PDD‐TURBT with second TUR (112 patients, PDD‐second group) or without second TUR (194 patients, PDD‐alone group). Oncologic outcomes (bladder cancer recurrence, progression, urothelial cancer‐specific mortality) and rates of residual tumor and risk stratification of non‐muscle‐invasive bladder cancer (NMIBC) after second TUR were evaluated. Results After propensity score‐matching 121 patients were included each in the WL‐alone and WL‐second groups, and 63 patients each in the PDD‐alone and PDD‐second groups. In the WL group, the second TUR was significantly associated with improved progression‐free ( p = 0.012) and urothelial cancer‐specific free survival ( p = 0.011), but not with recurrence‐free survival ( p = 0.93). Patients initially treated with PDD‐TURBT, and with a tumor diameter <30 mm and multifocality had a relatively high benefit from second TUR. The rates of residual tumor and risk stratification of NMIBC did not significantly differ between WL‐TURBT and PDD‐TURBT groups. Conclusions Our findings suggested that a second TUR could be omitted after an initial PDD‐TURBT in selected patients with high‐risk NMIBC.
Year:
2024
Year:
2022
Year:
2021
Year:
2020
Year:
2020
Year:
2020
Collaborators (4)
Jun Miki
Associate Professor
-
KIYOHIDE FUJIMOTO
Professor and Chair
Nara Medical University
Takuma Kato
Kagawa University
Takahiro Kimura
Jikei University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.